A Unique AIDS Vaccine Candidate For Multiple HIV Strains

描述：(申请人提供)开发一种安全有效的艾滋病 疫苗具有巨大的商业潜力和社会影响，是全国性的 优先考虑。针对艾滋病疫苗开发中出现的障碍，a 融合了一套新的概念和设计，开发出一种新的艾滋病 疫苗-佐剂系统。它包括一种特殊设计的免疫原HMP-gpl20， 两种针对B淋巴细胞的新型佐剂和一种新的疫苗配方 抗原佐剂。这可能会导致人们长期寻求的艾滋病疫苗，从而引发 对多种HIV的有效和持久的中和抗体反应 防止艾滋病毒感染和传播的菌株。在拟议的第一阶段 研究开发新的艾滋病疫苗佐剂系统，免疫动物， 检测阻断HIV gp20的一般抗体和中和抗体活性 绑定到DC-Sign。调查人员的经验，初步数据， 动物设施和公司的专业知识使科学团队胜任 以完成本提案中的目标。我们预计这部小说《爱滋病》 疫苗-佐剂系统将诱导较强的中和抗体活性和 为难以捉摸的疫苗和增强体液的新机制提供了一个模型 豁免权。构建的HMP-gpl20、新的佐剂和其他试剂将 第二阶段研究的基础。中和抗体活性将提供 第二阶段研究和开发的必要信息。

DESCRIPTION: (Provided by Applicant) Development of a safe and effective AIDS vaccine has tremendous commercial potential and social impact and is a national priority. In response to the obstacles presented in AIDS vaccine development, a set of new concepts and designs is integrated to develop a new AIDS vaccine-adjuvant system. It includes a special design of immunogen HMP-gpl20, two novel adjuvants targeting B lymphocytes, and a new formulation of vaccine antigen-adjuvant. It could lead to a long-sought AIDS vaccine that elicits effective and long lasting neutralizing antibody responses to multiple HIV strains to prevent HIV infection and transmission. In the proposed Phase I study we will develop a new AIDS vaccine-adjuvant system, immunize animals, and detect general and neutralizing antibody activities that block HIV gpl20 binding to DC-SIGN. The investigators' experience, the preliminary data, the animal facility, and the company expertise make the scientific team competent to complete the objectives in this proposal. We anticipate that this novel AIDS vaccine-adjuvant system will induce strong neutralizing antibody activity and provide a model for elusive vaccines and a novel mechanism to enhance humoral immunity. The constructed HMP-gpl20, new adjuvants, and other reagents will be the basis for Phase II study. The neutralizing antibody activity will provide necessary information for phase II research and development.